黑素瘤相关肿瘤浸润淋巴细胞的评价方法及免疫异质性研究进展
Research Progress on Evaluation Methods and Immune Heterogeneity of Tumor Infiltrating Lymphocytes in Melanoma
摘要: 肿瘤浸润淋巴细胞随着免疫治疗的日益兴起，作为一个重要的免疫参数，被证实可以预测免疫治疗的疗效，还可以提示预后。然而迄今为止，没有癌症分期算法包含免疫标记物。重要的是，对TIL浸润的多种成分也缺乏了解。该文综述了肿瘤浸润淋巴细胞在黑素瘤中的评估方法的进展，同时探讨了CD4+T淋巴细胞在黑素瘤中作用的研究进展。
Abstract: With the rise of immunotherapy, tumor-infiltrating lymphocytes, as an important immune param-eter, have been proved to predict the efficacy of immunotherapy and can also indicate the prognosis. To date, however, no cancer staging algorithm has included immune markers. Importantly, there is also a lack of understanding of the multiple components of TIL infiltration. This article reviews the progress of evaluation methods of tumor-infiltrating lymphocytes in melanoma, and discusses the role of CD4+T lymphocytes in melanoma.
文章引用：索雅力·齐齐格, 王丹妮, 万学峰. 黑素瘤相关肿瘤浸润淋巴细胞的评价方法及免疫异质性研究进展[J]. 临床医学进展, 2023, 13(10): 16476-16482. https://doi.org/10.12677/ACM.2023.13102307

参考文献

[1] Zidlik, V., Bezdekova, M. and Brychtova, S. (2020) Tumor Infiltrating Lymphocytes in Malignant Melanoma-Allies or Foes? Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, 164, 43-48. [Google Scholar] [CrossRef] [PubMed]
[2] Fortes, C., Mastroeni, S., Mannooranparampil, T.J., et al. (2015) Tu-mor-Infiltrating Lymphocytes Predict Cutaneous Melanoma Survival. Melanoma Research, 25, 306-311. [Google Scholar] [CrossRef] 
[3] Li, P., Li, F., Zhang, Y., Yu, X. and Li, J. (2023) Metabolic Diversity of Tumor-Infiltrating T Cells as Target for Anti-Immune Therapeutics. Cancer Immunology, Immunotherapy. [Google Scholar] [CrossRef] 
[4] Clark, W.H., Elder, D.E., Guerry, D., et al. (1989) Model Predicting Survival in Stage I Melanoma Based on Tumor Progression. JNCI: Journal of the National Cancer In-stitute, 81, 1893-1904. [Google Scholar] [CrossRef] [PubMed]
[5] Clemente, C.G., Mihm, M.C., Bufalino, R., Zurrida, S., Collini, P. and Cascinelli, N. (1996) Prognostic Value of Tumor Infiltrating Lymphocytes in the Vertical Growth Phase of Primary Cutaneous Melanoma. Cancer, 77, 1303-1310. [Google Scholar] [CrossRef] 
[6] Taylor, R.C., Patel, A., Panageas, K.S., Busam, K.J. and Brady, M.S. (2007) Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma. Journal of Clinical Oncology, 25, 869-875. [Google Scholar] [CrossRef] 
[7] Mandalà, M., Imberti, G.L., Piazzalunga, D., et al. (2009) Clinical and Histopathological Risk Factors to Predict Sentinel Lymph Node Positivity, Disease-Free and Overall Survival in Clinical Stages I-II AJCC Skin Melanoma: Outcome Analysis from a Single-Institution Prospectively Collected Database. European Journal of Cancer, 45, 2537- 2545. [Google Scholar] [CrossRef] [PubMed]
[8] Borges de Barros Primo, R., BritoNobre, A., Santos, B.N., et al. (2023) Impact of Clinical and Histopathological Characteristics on the Disease-Free Survival of Stage I-II Acral Melanoma Patients. International Journal of Dermatology, 62, 1281-1288. [Google Scholar] [CrossRef] [PubMed]
[9] Azimi, F., Scolyer, R.A., Rumcheva, P., et al. (2012) Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients with Cutaneous Melanoma. Journal of Clinical Oncology, 30, 2678-2683. [Google Scholar] [CrossRef] 
[10] Kishton, R.J., Sukumar, M. and Restifo, N.P. (2017) Metabolic Regulation of T Cell Longevity and Function in Tumor Immuno-therapy. Cell Metabolism, 26, 94-109. [Google Scholar] [CrossRef] [PubMed]
[11] Piras, F., Colombari, R., Minerba, L., et al. (2005) The Predictive Value of CD8, CD4, CD68, and Human Leukocyte Antigen-D-Related Cells in the Prognosis of Cutaneous Malignant Melanoma with Vertical Growth Phase. Cancer, 104, 1246-1254. [Google Scholar] [CrossRef] [PubMed]
[12] Xiao, M., Xie, L., Cao, G., et al. (2022) CD4+ T-Cell Epitope-Based Het-erologous Prime-Boost Vaccination Potentiates Anti-Tumor Immunity and PD-1/PD-L1 Immunotherapy. The Journal for ImmunoTherapy of Cancer, 10, e004022. [Google Scholar] [CrossRef] [PubMed]
[13] Kim, H.J. and Cantor, H. (2014) CD4 T-Cell Subsets and Tumor Immunity: The Helpful and the Not-So-Helpful. Cancer Immunology Research, 2, 91-98. [Google Scholar] [CrossRef] 
[14] Kruse, B., Buzzai, A.C., Shridhar, N., et al. (2023) CD4+ T Cell-Induced Inflammatory Cell Death Controls Immune- Evasive Tumours. Nature, 618, 1033-1040. [Google Scholar] [CrossRef] [PubMed]
[15] Saldanha, G., Flatman, K., Teo, K.W. and Bamford, M. (2017) A Novel Numerical Scoring System for Melanoma Tumor-infiltrating Lymphocytes Has Better Prognostic Value than Standard Scoring. The American Journal of Surgical Pathology, 41, 906-914. [Google Scholar] [CrossRef] 
[16] Park, C.K. and Kim, S.K. (2017) Clinicopathological Signif-icance of Intratumoral and Peritumoral Lymphocytes and Lymphocyte Score Based on the Histologic Subtypes of Cuta-neous Melanoma. Oncotarget, 8, 14759-14769. [Google Scholar] [CrossRef] [PubMed]
[17] Hendry, S., Salgado, R., Gevaert, T., et al. (2017) Assessing Tu-mor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointesti-nal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 24, 311-335. [Google Scholar] [CrossRef] 
[18] Weiss, S.A., Han, S.W., Lui, K., et al. (2016) Immunologic Heterogeneity of Tumor-Infiltrating Lymphocyte Composition in Primary Melanoma. Human Pathology, 57, 116-125. [Google Scholar] [CrossRef] [PubMed]
[19] Fridman, W.H., Zitvogel, L., Sautès-Fridman, C. and Kroemer, G. (2017) The Immune Contexture in Cancer Prognosis and Treatment. Nature Reviews Clinical Oncology, 14, 717-734. [Google Scholar] [CrossRef] [PubMed]
[20] Lyons, Y.A., Wu, S.Y., Overwijk, W.W., Baggerly, K.A. and Sood, A.K. (2017) Immune Cell Profiling in Cancer: Molecular Approaches to Cell-Specific Identification. NPJ Precision Oncology, 1, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
[21] Halse, H., Colebatch, A.J., Petrone, P., et al. (2018) Multiplex Immunohistochemistry Accurately Defines the Immune Context of Metastatic Melanoma. Scientific Reports, 8, Article No. 11158. [Google Scholar] [CrossRef] [PubMed]
[22] Maibach, F., Sadozai, H., SeyedJafari, S.M., Hunger, R.E. and Schenk, M. (2020) Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Frontiers in Immunology, 11, Article No. 2105. [Google Scholar] [CrossRef] [PubMed]
[23] Hutter, C. and Zenklusen, J.C. (2018) The Cancer Genome Atlas: Creating Lasting Value beyond Its Data. Cell, 173, 283-285. [Google Scholar] [CrossRef] [PubMed]
[24] Finotello, F. and Trajanoski, Z. (2018) Quantifying Tu-mor-Infiltrating Immune Cells from Transcriptomics Data. Cancer Immunology, Immunotherapy, 67, 1031-1040. [Google Scholar] [CrossRef] [PubMed]
[25] Peng, Q., Ren, B., Xin, K., et al. (2023) CYFIP2 Serves as a Prognostic Biomarker and Correlates with Tumor Immune Microenvironment in Human Cancers. European Journal of Medical Research, 28, Article No. 364. [Google Scholar] [CrossRef] [PubMed]
[26] Iglesia, M.D., Parker, J.S., Hoadley, K.A., Serody, J.S., Perou, C.M. and Vincent, B.G. (2016) Genomic Analysis of Immune Cell Infiltrates across 11 Tumor Types. JNCI: Journal of the National Cancer Institute, 108, djw144. [Google Scholar] [CrossRef] [PubMed]
[27] Paijens, S.T., Vledder, A., de Bruyn, M. and Nijman, H.W. (2021) Tu-mor-Infiltrating Lymphocytes in the Immunotherapy Era. Cellular & Molecular Immunology, 18, 842-859. [Google Scholar] [CrossRef] [PubMed]
[28] Dobrzanski, M.J., Reome, J.B., Hylind, J.C. and Rewers-Felkins, K.A. (2006) CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondif-ferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer. The Journal of Immunology, 177, 8191-8201. [Google Scholar] [CrossRef] [PubMed]
[29] Antony, P.A., Piccirillo, C.A., Akpinarli, A., et al. (2005) CD8+ T Cell Immunity against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells. The Journal of Immunology, 174, 2591-2601. [Google Scholar] [CrossRef] [PubMed]
[30] Barnes, T.A. and Amir, E. (2018) HYPE or HOPE: The Prog-nostic Value of Infiltrating Immune Cells in Cancer. British Journal of Cancer, 118, e5. [Google Scholar] [CrossRef] [PubMed]
[31] Fu, Q., Chen, N., Ge, C., et al. (2019) Prognostic Value of Tu-mor-Infiltrating Lymphocytes in Melanoma: A Systematic Review and Meta-Analysis. Oncoimmunology, 8, Article ID: 1593806. [Google Scholar] [CrossRef] 
[32] Becht, E., Giraldo, N.A., Germain, C., et al. (2016) Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 130, 95-190. [Google Scholar] [CrossRef] [PubMed]
[33] Qiu, L., Yu, Q., Zhou, Y., et al. (2018) Functionally Impaired Fol-licular Helper T Cells Induce Regulatory B Cells and CD14+ Human Leukocyte Antigen-DR− Cell Differentiation in Non-Small Cell Lung Cancer. Cancer Science, 109, 3751-3761.
[34] Mattes, J., Hulett, M., Xie, W., et al. (2003) Im-munotherapy of Cytotoxic T Cell-Resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-Dependent Process. Journal of Experimental Medicine, 197, 387-393. [Google Scholar] [CrossRef] [PubMed]
[35] Nishimura, T., Iwakabe, K., Sekimoto, M., et al. (1999) Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo. Journal of Experimental Medicine, 190, 617-627. [Google Scholar] [CrossRef] [PubMed]
[36] Bettelli, E., Carrier, Y., Gao, W., et al. (2006) Reciprocal Developmen-tal Pathways for the Generation of Pathogenic Effector TH17 and Regulatory T Cells. Nature, 441, 235-238. [Google Scholar] [CrossRef] [PubMed]
[37] Hamaï, A., Pignon, P., Raimbaud, I., et al. (2012) Human T(H)17 Im-mune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ-Secreting Cells as They Differentiate into Ef-fector T Cells in Vivo. Cancer Research, 72, 1059-1063. [Google Scholar] [CrossRef] 
[38] Quezada, S.A., Simpson, T.R., Peggs, K.S., et al. (2010) Tumor-Reactive CD4(+) T Cells Develop Cytotoxic Activity and Eradicate Large Established Melanoma after Transfer into Lymphopenic Hosts. Journal of Experimental Medicine, 207, 637-650. [Google Scholar] [CrossRef] [PubMed]
[39] Hirschhorn-Cymerman, D., Budhu, S., Kitano, S., et al. (2012) Induc-tion of Tumoricidal Function in CD4+ T Cells Is Associated with Concomitant Memory and Terminally Differentiated Phenotype. Journal of Experimental Medicine, 209, 2113-2126. [Google Scholar] [CrossRef] [PubMed]
[40] Curran, M.A., Geiger, T.L., Montalvo, W., et al. (2013) Systemic 4-1BB Activation Induces a Novel T Cell Phenotype Driven by High Expression of Eomesodermin. Journal of Experimental Medicine, 210, 743-755. [Google Scholar] [CrossRef] [PubMed]
[41] Thomas, W.D. and Hersey, P. (1998) TNF-Related Apoptosis-Inducing Ligand (TRAIL) Induces Apoptosis in Fas Ligand-Resistant Melanoma Cells and Mediates CD4 T Cell Killing of Target Cells. The Journal of Immunology, 161, 2195-2200. [Google Scholar] [CrossRef] 
[42] Durgeau, A., Virk, Y., Corgnac, S. and Mami-Chouaib, F. (2018) Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Frontiers in Immunology, 9, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[43] Busam, K.J., Antonescu, C.R., Marghoob, A.A., et al. (2001) Histologic Classification of Tumor-Infiltrating Lymphocytes in Primary Cutaneous Malignant Melanoma. A Study of In-terobserver Agreement. American Journal of Clinical Pathology, 115, 856-860. [Google Scholar] [CrossRef] 

为你推荐